Sakar Healthcare Limited (NSE: SAKAR) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹2,393 Cr, it ranks #1,158 by market cap among the 6,197 Indian listed companies on FinBizNet, and #20 of 63 in Pharmaceuticals. At ₹1,045.90 (as of 16 Nov 2026), the share price is 15.0% below its 52-week high of ₹1,229.85 and 189.0% above its 52-week low of ₹361.90. The share price is up 177.8% over one year and up 13.5% over three months.
| Current Price | ₹1,045.90 |
|---|---|
| Market Cap | ₹2,393 Cr |
| NSE Symbol | SAKAR |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 77.9 |
| Return on Equity | 9.99% |
| Return on Assets | 6.51% |
| 52-Week Range | ₹361.90 – ₹1,229.85 |
| 1-Year Price Change | +177.8% |
| 3-Month Price Change | +13.5% |
| Beta (1Y) | -0.15 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.sakarhealthcare.com |
| Revenue | ₹87 Cr |
|---|---|
| Net Profit | ₹11 Cr |
| Net Margin | 12.9% |
| EPS (Basic) | ₹5.08 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sakar Healthcare Limited reported revenue of ₹87 Cr in Q2 FY27, up 51.9% from ₹58 Cr in Q2 FY26 and up 19.8% from ₹73 Cr in Q1 FY27. It posted a net profit of ₹11 Cr for the quarter, against a net profit of ₹5 Cr in Q2 FY26 (up 149.1%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹50 Cr (Q4 FY25) to ₹87 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹87 Cr | ₹11 Cr | 12.9% |
| Q1 FY27 | ₹73 Cr | ₹10 Cr | 14.1% |
| Q4 FY26 | ₹71 Cr | ₹11 Cr | 15.5% |
| Q3 FY26 | ₹70 Cr | ₹10 Cr | 14.6% |
| Q2 FY26 | ₹58 Cr | ₹5 Cr | 7.9% |
| Q1 FY26 | ₹53 Cr | ₹5 Cr | 8.9% |
| Q4 FY25 | ₹50 Cr | ₹6 Cr | 11.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.70% of Sakar Healthcare Limited's shares as of Sept 2026, against 52.86% in Sept 2025 (−1.16 percentage points). Delivery averaged 45.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
1. Manufacturing of Pharmaceutical Products-This segment manufactures and sells pharmaceutical products in various forms, such as liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables in ampoules and vials, and lyophilized injections.
1. Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Sakar Healthcare Limited | ₹2,393 Cr | 77.9 | 9.99% | ₹87 Cr | +177.8% |
Listed by market capitalisation. Ratios are shown for context only.
Sakar Healthcare Limited is trading at ₹1,045.90, with a market capitalisation of ₹2,393 Cr.
Sakar Healthcare Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sakar Healthcare Limited has a P/E of 77.9 and a return on equity of 9.99%.
Sakar Healthcare Limited is listed on the NSE under the symbol SAKAR.
Sakar Healthcare Limited's share price is up 177.8% over one year and up 13.5% over three months. Its 52-week range is ₹361.90 to ₹1,229.85.
In Q2 FY27, Sakar Healthcare Limited reported revenue of ₹87 Cr and net profit of ₹11 Cr, with basic EPS of ₹5.08 (consolidated, parsed from the company's exchange filing).
Sakar Healthcare Limited reported revenue of ₹87 Cr in Q2 FY27, up 51.9% from ₹58 Cr in Q2 FY26 and up 19.8% from ₹73 Cr in Q1 FY27.
Promoters held 51.70% of Sakar Healthcare Limited's shares as of Sept 2026, against 52.86% in Sept 2025 (−1.16 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.